Patent '893 is for racemic mixture of Liptor which expires on March 2010. However, another patent, covering Lipitor (995) enantiomeric salt, expires in May 2011. Even though court ruled against PFE on '995 patent, I think they are fighting on this and now the settlement happened.
Because Ranbaxy holds the firstfiler 180-day generic marketing exclusivity for atorvastatin, this prevents other generics from launching a generic Lipitor in the US before May 30, 2012. (Pfizer holds the right to launch an authorized generic.)
Market Data 
Markets 
AI
